Solventum Corp (SOLV) Stock Price & Analysis
Solventum Corp (SOLV) rose 4.70% to USD 82.46 as of June 9, 2026 at 23:55 UTC, according to Nexqual real-time market data.
SOLV last closed at USD 78.76; the session ranged USD 79.35–82.57 on volume of 1,414,042 shares. Market capitalization is $14.28B, with a 52-week range of USD 62.38–88.2 (NYQ). Source: Nexqual, June 9, 2026 at 23:55 UTC.
Key Statistics (as of June 9, 2026 at 23:55 UTC)
| Price | USD 82.46 |
|---|---|
| Change | ▲ 4.70% (up) |
| Previous Close | USD 78.76 |
| Open | USD 79.65 |
| Day Range | USD 79.35 – 82.57 |
| 52-Week Range | USD 62.38 – 88.2 |
| Volume | 1,414,042 shares |
| Market Cap | $14.28B |
| Exchange | NYQ |
Technical Analysis (SOLV)
Nexqual's technical model rates SOLV "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:55 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 68.37 (neutral) |
| vs SMA50 | Above (USD 71.43) |
| MACD | 2.53 (positive) |
Analyst Ratings (SOLV)
Wall Street analysts rate SOLV "Buy" based on 13 analysts, with a mean price target of USD 82.15 (range USD 60–100), per Nexqual as of June 9, 2026 at 23:55 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 82.15 |
| High Target | USD 100 |
| Low Target | USD 60 |
| Buy / Hold / Sell | 7 / 5 / 3 |
Earnings (SOLV)
| Next Earnings Date | 2026-05-05 |
|---|---|
| EPS Estimate | USD 1.89 |
| Revenue Estimate | $2.15B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.48 vs est 1.35 ▲ beat |
| 2025-12-31 | USD 1.57 vs est 1.5 ▲ beat |
| 2025-09-30 | USD 1.5 vs est 1.43 ▲ beat |
| 2025-06-30 | USD 1.69 vs est 1.45 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
Financials & Fundamentals (SOLV)
| Total Revenue | $8.26B |
|---|---|
| Revenue Growth (YoY) | -3.00% |
| Gross Margin | +53.65% |
| Operating Margin | +5.58% |
| Profit Margin | +17.33% |
| ROE | +34.79% |
| Debt / Equity | 106.46 |
| Current Ratio | 1.07 |
| Total Cash | $561.00M |
| Total Debt | $5.29B |
| Free Cash Flow | $378.50M |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
Financial Health Score (SOLV)
Nexqual rates Solventum Corp's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:55 UTC.
| Growth | Mixed — Revenue +0.9% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 54%, operating 6% |
| Balance Sheet | Mixed — $561M cash vs $5.29B debt |
| Cash Flow | Mixed — FCF $379M, slim 4.5% margin |
| Efficiency | Strong — ROE 35%, ROA 2.7% |
Ownership (SOLV)
| Insider Ownership | +15.07% |
|---|---|
| Institutional Ownership | +76.53% |
| Shares Outstanding | 173.17M |
| Float | 147.07M |
| Short % of Float | +5.36% |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
Leadership (SOLV)
Solventum Corp is led by Bryan C. Hanson (age 58), CEO & Director, per Nexqual as of June 9, 2026 at 23:55 UTC.
| CEO & Director | Bryan C. Hanson (age 58) |
|---|---|
| Executive VP & CFO | Wayde D. McMillan (age 55) |
| Senior Vice President of Investor Relations & External Finance Communications | Amy Wakeham |
| Chief Strategy & Corporate Development Officer | Rachel H. Ellingson (age 55) |
Major Backers & Investors (SOLV)
Notable institutional backers of Solventum Corp include Independent Franchise Partners, LLP, Trian Fund Management, LP, Davis Selected Advisers, according to Nexqual as of June 9, 2026 at 23:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Independent Franchise Partners, LLP | 9.09% |
| Trian Fund Management, LP | 4.76% |
| Davis Selected Advisers | 3.66% |
| Invesco | 3.63% |
| Boston Partners | 2.26% |
| John Hancock Funds III-Disciplined Value Mid Cap Fund | 1.6% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 17.31% |
| BlackRock | 7.15% |
| State Street | 4.72% |
| Geode Capital | 2.74% |
Source: Nexqual, June 9, 2026 at 23:55 UTC.
From Solventum Corp's Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Our business segment R&D organizations are responsible for the full product development life cycle, leveraging industry insights, domain-specific expertise in end-to-end product development, and a detailed understanding of customer applications 6 Table of Contents and usability to innovate in both new and marketed products.
- Intellectual Property Development and protection of our proprietary technologies through IP rights is a strategic priority for our business.
- To protect our proprietary technologies, Solventum relies on a combination of patent, design, utility model, trademark, copyright, and trade secret protections as well as regulatory exclusivity periods and confidentiality agreements.
- Our supply chain resiliency program consisting of regional sources of supply, dual-source manufacturing capabilities and vertically integrated operations presents a competitive advantage by providing a reliable supply of products to our customers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KVUE | Kenvue Inc. | USD 17.92 | ▲ 1.19% |
| GEHC | GE HealthCare Technologies Inc. | USD 66.01 | ▲ 2.07% |
| VLTO | Veralto Corp | USD 86.16 | ▲ 0.13% |
| RVTY | Revvity, Inc. | USD 104.13 | ▲ 5.86% |
| OGN | Organon & Co. | USD 13.4 | ▲ 0.3% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:55 UTC. This page is informational and not investment advice.